Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.53 |
| ▸ | CRYZ | Q08257 | 1/20 | 0.53 |
| ▸ | VAT1 | Q99536 | 1/20 | 0.53 |
| ▸ | RTN4 | Q9NQC3 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25637238 | 0.85 | KRAS (0.39) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29766036 | 0.84 | KRAS (0.58) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16636888 | 0.84 | KRAS (0.58) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL17030811 | 0.83 | KRAS (0.64) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL25637215 | 0.80 | KRAS (0.38) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18135238 | 0.79 | KRAS (0.56) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL17030812 | 0.78 | KRAS (0.80) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL22560898 | 0.77 | KRAS (0.52) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29765668 | 0.76 | KRAS (0.61) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16636983 | 0.76 | KRAS (0.61) | KRASEGFRHMOX2CRYZVAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174526-A1 | BENZOTHIAZOLYL BIARYL COMPOUND, AND PREPARATION METHOD AND USE | SHANGHAI RINGENE THERAPEUTICS CO. LTD (CN) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174526-A1 | BENZOTHIAZOLYL BIARYL COMPOUND, AND PREPARATION METHOD AND USE | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 373/4885HMOX2 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.